R&D Tariff turbulence: Navigating US trade shifts in the medtech... The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical and economic uncertainty.
News Sanofi pledges a $20 billion investment programme in the US Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
News Pharma still in waiting mode after UK-US trade agreement Hopes that the UK-US trade agreement would give some clarity on the situation for pharmaceuticals proved optimistic.
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News UK trumpets a trade deal with India - but pharma isn't happy Various industries have welcomed news of a trade deal between the UK and India, but Britain's pharma sector isn't among them.
News GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face